josephinejones (@_JosephineJones), D Nile ist http://josephinejones.wordpress.com/2013/01/23/happy-birthday-dr-burzynski-and-goodbye-antineoplastons/comment-page-1/#comment-8921

[1]

“Please provide evidence that people are being paid to write about Burzynski”

“The very idea is ludicrous” [2]
——————————————————————
“It was probably the worst $15 I ever spent, but at least it’s tax-deductable for this blog” [3]

So, basically Gorski has money that he would otherwise have to pay instead of it being “tax-deductable” for his blog
======================================
“As far as saving lives is concerned – as I’ve explained already – Burzynski has never provided reliable evidence that antineoplastons work, despite having used them on cancer patients since the 1970s, and despite decades of “clinical trials””
——————————————————————
He does NOT need to

The FDA has already done it for him

The FDA’s Drug Review Process:

Ensuring Drugs Are Safe and Effective, advises:

“[T]he emphasis in Phase 2 is on EFFECTIVENESS”

“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″ [4]
——————————————————————
9/3/2004 – FDA granted “orphan drug designation” (“ODD”) for Antineoplastons (A10 & AS2-1 Antineoplaston) for treatment of patients with brain stem glioma [5]

.10/30/2008 – FDA granted “orphan drug designation” (“ODD”) for Antineoplastons (A10 and AS2-1 Antineoplaston) for treatment of gliomas [5]
——————————————————————
9/2004 – Antineoplaston AS2-1 received orphan drug status from the FDA for the treatment of brain stem glioma [6]

2008 – US orphan drug designation was extended to include all gliomas [6]
——————————————————————
80 evaluable patients in Phase II trial showed IV antineoplastons therapy resulted in: [7]

32% – complete or partial responses
43% – stable disease

36% – Overall survival at 2 years
25% – Overall survival at 5 years
======================================
“Indeed, as I’ve also explained, Burzynski can’t advertise antineoplastons as safe and effective and can no longer give antineoplastons to new patients”
——————————————————————
He doesn’t need to

The FDA has already done it for him
======================================
“Instead, antineoplastons seem to be promoted by word of mouth – by which I mean pseudonymous comments on blogs, online forums and social media”
——————————————————————
What’s your point ?

JosephineJones is a pseudonym
======================================
“And if you’re going to accuse people of writing “shit”, please specify who you refer to and what your specific objections are”
——————————————————————
Well, I just proved that you were writing “shit”
======================================
“If you believe anything I’ve written is inaccurate or in any way misleading, I would appreciate it if you could let me know so I can take steps to correct or clarify”
——————————————————————
Reply

Didymus Judas Thomas on September 23, 2013 at 3:23 pm

Your comment is awaiting moderation

JJ, you know you do NOT want any evidence

That’s why you block people on your blog

DJT 🙂
======================================
REFERENCES:
======================================
[1] – 9/22/2013 – josephinejones on September 22, 2013 at 10:08 pm
——————————————————————
http://josephinejones.wordpress.com/2013/01/23/happy-birthday-dr-burzynski-and-goodbye-antineoplastons/comment-page-1/#comment-8921
======================================
[2] – 9/22/2013 – Josephine Jones (@_JosephineJones) tweeted at 4:15pm – 22 Sep 13:

“THE SKEPTICS ARE PAID TO PUT THIS SHIT ABOUT BURZYNSKI” josephinejones.wordpress.com/2013/01/23/hap… Any evidence for that? #Burzynski
======================================
[3] – 6/3/2013 – In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence
——————————————————————
http://scienceblogs.com/insolence/2013/06/03/in-which-the-latest-movie-about-stanislaw-burzynskis-cancer-cure-is-reviewed-with-insolence/
======================================
[4] – 4/25/2013 – Burzynski: The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-the-fdas-drug-review-process-ensuring-drugs-are-safe-and-effective/
======================================
[5] – 2013
——————————————————————
http://biz.yahoo.com/e/130715/bzyr10-q.html
======================================
[6]
——————————————————————
http://www.medmk.com/mm/add/1068_ad3.htm
======================================
[7] – BioCentury

5/18/2009 Volume217 Number 22

Clinical Results

BioCentury Part II MAY 18, 2009 PAGE B10 OF 22

Burzynski Research Institute Inc. (OTCBB:BZYR), Houston, Texas

Product: Antineoplastons (ANP) therapy

Business: Cancer

BioCentury Part II MAY 18, 2009 PAGE B11 OF 22

Description: Combination of Atengenal (antineoplaston A10) and Astugenal (antineoplaston AS2-1)

Indication: Treat advanced non-operable brainstem glioma (BSG)

Endpoint: Response rate and overall survival

Data presented at Quadrennial Meeting of the World Federation of Neuro-Oncology in Yokohama
——————————————————————
http://www.pluristem.com/e_pr/051809bc.pdf
======================================

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s